NBP | Ticker Profile - Titan Protect

NBP

NovaBridge Biosciences

Healthcare · Biotechnology · NGM

$1.64

Data: 2026-05-15

✗ ETHICAL FAIL

MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$222M

Total market value of the company

Trailing P/E

0.00

Forward P/E

-1.81

Based on estimated future earnings — lower means cheaper

Rev Growth

0.0%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-40.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$8.00

+386% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 3 analysts covering this stock

About NovaBridge Biosciences

NovaBridge Biosciences, a biotechnology company, focuses on the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. It is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; VIS-101, a bispecific antibody, which is in Phase 2b clinical trail for Wet AMD and other retinal diseases; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. The company has a strategic licensing agreement with AffaMed and AskGene to develop and commercialize VIS-101 to Visara. It also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

https://novabridge.com

Country: United States Employees: 30 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

1.4% PASS

Debt must be below 33% of total assets

Cash Ratio

95.0% FAIL

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.516

Good returns relative to risk taken

Kelly Fraction

-0.0056

No positive edge detected — the data suggests staying out

Calmar Ratio

0.046

Drawdown risk outweighs the returns — higher risk profile

Annual Return

3.4%

Historical annualised return based on price data

Max Drawdown

-74.4%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.56

Significantly more volatile than the market

52W High

$6.79

76% below the year high

52W Low

$0.86

92% above the year low

Avg Volume

955,566

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

8.0%

Moderate short interest

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.48

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.01

Conservative use of debt — low financial risk

Current Ratio

8.09

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

7.91

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-37,113,124

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-88,340,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$9.00

Target Median

$8.00

Target Low

$7.00

Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date	Insider	Title	Type	Shares	Value
2026-04-24	HAGLER MARK ARNOLD	President		230,000	$577,300

Source: SEC Form 4 filings via public data. View all insider activity at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Before you go